Clinuvel Pharmaceuticals Limited

ASX CUV.AX

Clinuvel Pharmaceuticals Limited Net Cash Used For Investing Activities for the year ending June 30, 2024: USD -19.36 M

Clinuvel Pharmaceuticals Limited Net Cash Used For Investing Activities is USD -19.36 M for the year ending June 30, 2024, a -2,730.95% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Clinuvel Pharmaceuticals Limited Net Cash Used For Investing Activities for the year ending June 30, 2023 was USD -683.82 K, a -128.08% change year over year.
Clinuvel Pharmaceuticals Limited Net Cash Used For Investing Activities for the year ending June 30, 2022 was USD -299.82 K, a 53.19% change year over year.
Clinuvel Pharmaceuticals Limited Net Cash Used For Investing Activities for the year ending June 30, 2021 was USD -640.56 K, a -4.40% change year over year.
Clinuvel Pharmaceuticals Limited Net Cash Used For Investing Activities for the year ending June 30, 2020 was USD -613.56 K, a -239.18% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

ASX: CUV.AX

Clinuvel Pharmaceuticals Limited

CEO	Dr. Philippe Jacques Wolgen M.B.A., M.D.
IPO Date	Feb. 11, 2001
Location	Australia
Headquarters	535 Bourke Street
Employees	16
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Key trends

Past 5 years